Bevasiranib: Additional Phase II data

In the double-blind, U.S. Phase II C.A.R.E. trial in 129 patients, bevasiranib was safe and well tolerated. Patients received 0.2, 1.5 or 3 mg of intravitreal bevasiranib per eye at the start of the s...